Based upon drug class and clinical relevance, we further specified four key lead compounds for mechanistic characterization of immunostimulatory properties, including effects on CD8+ T-cell proliferation and cytokine profile, tumor cell antigen presentation, and induction of immunogenic cell death markers. Here, CD8A is linked to neoplasm.